Si-Jun-Zi-Tang combined with temozolomide produces synergistic anti-melanoma effects via inhibiting MGMT and ATR/CHK1 pathways

Keyphrases

• Anti-melanoma 100%
• Sijunzi Tang 100%
• ATR-CHK1 100%
• Temozolomide 100%
• Checkpoint Kinase 1 (CHK1) 23%
• Melanoma Cells 17%
• Synergize 17%
• Cytotoxicity 11%
• Immunoblotting 11%
• Hepatotoxicity 11%
• Proteasomal Degradation 11%
• Ethanol 5%
• Highly Effective 5%
• Serum Levels 5%
• DNA Damage 5%
• MRNA Level 5%
• Comet Assay 5%
• Melanoma Growth 5%
• Protein Level 5%
• Melanoma 5%
• Quantitative PCR 5%
• Low Toxicity 5%
• Human Body 5%
• Therapeutic Agents 5%
• Network Pharmacology 5%
• B16 Melanoma 5%
• Si Effect 5%
• Reflux Extraction 5%
• Cell Counting kit-8 (CCK-8) 5%
• Low Protein 5%
• Cdc25 5%
• A375 Cells 5%
• Severe Toxicity 5%
• A2058 5%
• Malignant Melanoma 5%
• ATR-Chk1 Pathway 5%
• Keratinocyte Cells 5%

Pharmacology, Toxicology and Pharmaceutical Science

• Melanoma 100%
• Temozolomide 100%
• Cytotoxicity 12%
• Western Blot 12%
• Hepatotoxicity 12%
• Antiinfective Agent 6%
• Messenger RNA 6%
• Comet Assay 6%
• Network Pharmacology 6%
• Melanoma B16 6%